Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
The most effective method to Guarantee Scholastic Honesty in Web-based Degrees - 2Scientists solve the mystery of the prehistoric 'Burtele Foot'
- 3What is the 'Survivor 50' Challenge? Hidden immunity idols will be up for grabs in every U.S. state.
- 4Potential Houthi threat to Red Sea shipping could further damage global economy
- 5Courageous Climbing: Trails and Stuff for Outside Lovers
- Satellite observations offer insight into a tsunami's early stages
- Deaths reported in Lebanon as Israel and Hezbollah exchange attacks
- First stop, the Moon. Next stop, Mars? Why Nasa's mission matters
- The Fate of Rest: Patterns in Shrewd Beds
- Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip
- Creativity Revealed: A Survey of \Making Shocking Looks\ Cosmetics Item
- Figure out How to Store Your Gold Ventures: A Thorough Aide safely
- Vote in favor of the juice that you love for its medical advantages!
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
